GlassScriptPhysician profile
Ronald G Navone
NPI 1225144934
$13,227.76
in general payments reported to CMS, 2019-2025
47 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,534 · 2020: $2,284 · 2021: $2,207 · 2022: $1,309 · 2023: $1,373 · 2024: $1,921 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,872 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,872.45 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,573.63 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Amgen INC. | $1,475.59 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $969.00 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $945.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $863.85 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $758.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $727.20 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $643.95 | 2019-2022 | |
| Abbvie INC. | $626.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $517.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.88 | 2019-2024 | Xifaxan |
| Mylan Specialty L.P. | $418.57 | 2019-2024 | Yupelri |
| Corcept Therapeutics | $309.39 | 2024-2025 | Korlym |
| Forte Bio-Pharma LLC | $282.60 | 2020-2021 | |
| Allergan, INC. | $280.17 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Navone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.